At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.
-
Researchers want to find the highest dose of DISC-0974 to use in people with myelofibrosis and anemia. Myelofibrosis happens when bone marrow cells called fibroblasts make too much fibrous (scar) tissue. The bone marrow is not able to make enough blood cells, which leads to anemia. Anemia is a reduced number of red blood cells, and it causes tiredness and shortness of breath.
-
Researchers are assessing trametinib and azacitidine alone and with other drugs to treat leukemia in young people. The people in this study have newly diagnosed juvenile myelomonocytic leukemia (JMML).
-
Researchers are assessing a new way of giving isatuximab with carfilzomib and dexamethasone in people with multiple myeloma. Isatuximab is injected under the skin using a wearable device attached to the skin of the stomach area. Carfilzomib will be given intravenously (by vein). Dexamethasone can be taken orally (by mouth) or intravenously. 
-
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
-
The usual treatment for brain metastases (cancer that spread to the brain) is a single treatment of stereotactic radiosurgery (SRS). SRS uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor.
- A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Full Title Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Purpose
In this study, researchers are assessing the safety and effectiveness of using the drug ruxolitinib in patients with T-cell lymphoma or natural killer (NK)-cell lymphoma that has come back or continued to grow despite prior treatment. Ruxolitinib is already approved for treating a bone marrow disease called myelofibrosis. It works by inhibiting a protein called JAK, which works with another protein called STAT to promote the growth of many T-cell and NK-cell lymphomas. By blocking JAK, ruxolitinib may cause lymphomas to shrink.
Ruxolitinib is taken orally (by mouth).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment.
- At least two weeks must pass between the completion of previous chemotherapy and entry into the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 212-639-4839.
Protocol
16-1542Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT02974647ClinicalTrials.gov
-
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues in the body. Researchers in this study are comparing different chemotherapy-based treatments for children and young adults with very low-risk RMS, low-risk RMS, and RMS with DNA mutations, with treatment tailored to the predicted aggressiveness of each patient's cancer. The standard chemotherapy drugs participants will receive include vincristine, dactinomycin, and cyclophosphamide.
-
Researchers are assessing nivolumab and ipilimumab immunotherapy with or without cabozantinib to treat advanced nasopharyngeal cancer. The people in this study have nasopharyngeal cancer that recurred (came back) or metastasized (spread). In addition, the cancer cannot be cured with other therapies.
-
Researchers want to see if bemdaneprocel improves symptoms in people with Parkinson's disease (PD). PD symptoms are due to a loss of cells that make a chemical in your brain called dopamine.